Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Feb

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer

AI Tool Predicts Cardiac Events in Patients With Cancer and Acute Coronary Syndrome

Overall Survival With 3 vs 6 Months of Adjuvant Oxaliplatin Plus Fluoropyrimidine for Colorectal Cancer

Adjuvant Aumolertinib in EGFR-Mutated NSCLC

Deep Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC